Adquey (difamilast) - PA, NF

Indications for Prior Authorization

Adquey (difamilast)
  • For diagnosis of Atopic Dermatitis
    Indicated for the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis.

Criteria

Adquey

Prior Authorization (Initial Authorization)

Length of Approval: 6 Month(s)
For diagnosis of Atopic Dermatitis

  • Diagnosis of mild to moderate atopic dermatitis
  • AND
  • Patient is 2 years of age or older
  • AND
  • Prescribed by or in consultation with one of the following:
    • Dermatologist
    • Allergist/Immunologist
    AND
  • Paid claims or submission of medical records (e.g., chart notes) confirming a trial and failure of a minimum 30-day supply (14-day supply for topical corticosteroids), contraindication, or intolerance to both of the following [2-3]:
    • Medium or higher potency topical corticosteroid
    • Generic topical calcineurin inhibitor (e.g., tacrolimus ointment)
    AND
  • Not used in combination with other nonsteroidal topical agents or systemic therapies for atopic dermatitis*
Adquey

Prior Authorization (Reauthorization)

Length of Approval: 12 Month(s)
For diagnosis of Atopic Dermatitis

  • Patient demonstrates positive clinical response to therapy as evidenced by ONE of the following [1-3]
    • Reduction in body surface area involvement from baseline
    • Reduction in pruritus severity from baseline
    • Improvement in quality of life from baseline
    AND
  • Paid claims or submission of medical records (e.g., chart notes) confirming a trial and failure of a minimum 30-day supply (14-day supply for topical corticosteroids), contraindication, or intolerance to both of the following [2-3]:
    • Medium or higher potency topical corticosteroid
    • Generic topical calcineurin inhibitor (e.g., tacrolimus ointment)
    AND
  • Not used in combination with other nonsteroidal topical agents or systemic therapies for atopic dermatitis*
Adquey

Non Formulary

Length of Approval: 6 Month(s)
For diagnosis of Atopic Dermatitis

  • Submission of medical records (e.g., chart notes) confirming a diagnosis of mild to moderate atopic dermatitis
  • AND
  • Patient is 2 years of age or older
  • AND
  • Prescribed by or in consultation with one of the following:
    • Dermatologist
    • Allergist/Immunologist
    AND
  • Paid claims or submission of medical records (e.g., chart notes) confirming a trial and failure of a minimum 30-day supply (14-day supply for topical corticosteroids), contraindication, or intolerance to both of the following [2-3]:
    • Medium or higher potency topical corticosteroid
    • Generic topical calcineurin inhibitor (e.g., tacrolimus ointment)
    AND
  • Not used in combination with other nonsteroidal topical agents or systemic therapies for atopic dermatitis*
P & T Revisions

1970-01-01, 2026-10-26, 2026-10-08, 2025-11-06, 2024-12-05, 2023-11-01, 2023-08-18, 2022-11-02, 2022-08-24, 2021-10-25, 2021-09-30, 2021-08-24, 2020-10-26, 2020-08-21, 2020-03-31, 2019-09-24, 2019-08-22

  1. Adquey Prescribing Information. Acrotech Biopharma, Inc . East Windsor, NJ. February 2026.
  2. Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):e1-e20.
  3. Davis DMR, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in pediatric patients. Published online April 7, 2026. https://www.jaad.org/action/showPdf?pii=S0190-9622%2826%2900343-9.

  • 2026-10-26: New program
  • 2026-10-08: New program
  • 2025-11-06: 2025 Annual Review. No criteria changes. Updated references.
  • 2024-12-05: 2024 Annual Review. No criteria changes.
  • 2023-11-01: Annual Review, no changes.
  • 2023-08-18: 2024 Medicare Implementation - No Changes
  • 2022-11-02: 2022 Annual Review
  • 2022-08-24: 2023 Guideline Loading created from HPMS Submission file
  • 2021-10-25: Annual Review - No criteria changes
  • 2021-09-30: 2022 formulary note addition - no changes to criteria
  • 2021-08-24: 2022 Medicare Implementation - No Changes
  • 2020-10-26: No changes to clinical criteria annual review
  • 2020-08-21: 2021 Guideline Loading created from HPMS Submission file
  • 2020-03-31: Program Update
  • 2019-09-24: updated references removed elidel reference no longer on GL
  • 2019-08-22: 2020 Migration Upload - formulary strategy update